Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
NEO.US
id: 491, Created by Stan Vick Chase, Scout
Daniel Goldenberg, et al. v. NeoGenomics, Inc., et al.
How it works?
- We find Attorney for the Case
- Attorney files case on behalf of Investors
- You get updates and receive payout in case of success
Would it cost me anything?
- No, you do not pay anything out of your pocket neither to us, nor to Attorney
- Attorneys get % fee in case of success
- Platform charges service fee from Attorneys
What are the chances for success?
Every Case is unique, but statistically, 47% of Cases end up with a settlement.
Please see below recent successful cases:
How it works?
- We find Attorney for the Case
- Attorney files case on behalf of Investors
- You get updates and receive payout in case of success
Would it cost me anything?
- No, you do not pay anything out of your pocket neither to us, nor to Attorney
- Attorneys get % fee in case of success
- Platform charges service fee from Attorneys
What are the chances for success?
Every Case is unique, but statistically, 47% of Cases end up with a settlement.
Please see below recent successful cases:
On April 27, 2022, NeoGenomics (NEO) disclosed & admitted material negative facts:
- “higher payroll and payroll related costs” which drove decreased profit and increased operating expenses,
- its portfolio of cancer tests “is weighted to legacy” tests “while the market is moving towards larger, more comprehensive panels.”
- it had “not kept up” with competitors that were offering more in-demand technologically advanced cancer tests.
Earlier, on March 28, 2022, NeoGenomics disclosed the departure of its CEO and simultaneously reduced its financial guidance largely due to “higher than anticipated” costs.
Going back on November 4, 2021, NeoGenomics revealed that it was, “conducting an internal investigation that focuses on the compliance of certain consulting and service agreements with federal healthcare laws and regulations” including “those relating to fraud, waste, and abuse,” and had “accrued a reserve of $10.5 million for potential damage and liabilities associated with the federal healthcare program revenue received spanning multiple years.”
These appeared facts and disclosures caused the value of NeoGenomics stock to decline dramatically, resulting in significant harm to investors.
Taking all representations and appeared facts into account, Investors have reasons to suspect the Company and its Leaders violated the rights of shareholders, damaging the value of their holdings.
Alleged Offence
Mismanagement,
Misleading Statements,
Financial Misrepresentation,
Fraud,
Failure to Disclose,
Malpractice,
Negligence,
Breach of Fiduciary duty,
Omissions
Suspected Party
Directors,
Management,
Investment Bank,
Service Provider,
Research Entity
Security Type
Stocks
Trade Direction
Long
Shock Event Date
26 April 2022
Filing date
06 December 2022
Court
Southern District of New York
Judge
Hon. Paul A. Engelmayer